Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C

Abstract

This double-blind, placebo-controlled trial provides preliminary data in support of antidepressant pre-treatment in hepatitis C virus patients with elevated depressive symptoms at baseline.